All In Biotech

Drug Trial Radar · NCT04984434

Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma

A First-in-human, Open-label, Multiple Center Phase 1 Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetic, Immunogenicity, and Preliminary Efficacy of F182112 in Patients With Relapsed or Refractory Multiple Myeloma.

Last checked: Nov 19, 2026Latest source record: Jul 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

68

Planned (sponsor's estimate)

Start

Jul 30, 2021

Primary completion

Jul 30, 2023

Study completion Dec 30, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a Multiple center, Open-label, dose escalation Phase Ⅰ clinical study. The purpose is to evaluate the safety and tolerability of F182112 when infused intravenously (IV) and determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of F182112 when infused IV.

Conditions

  • Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma

Interventions

  • F182112Drug

    Eight dose cohorts: 0.01, 0.1, 0.3, 1, 3, 10, 20 and 30 μg/kg) d1 treat every weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTsTime frame: Up to 28 days
  2. Maximum Tolerated Dose (MTD)Time frame: Approximately 12 months
  3. RP2DTime frame: Approximately 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shaohong Yin

    Linyi, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.